The pharmacokinetics, oral bioavailability, cerebrovascular permeability and biotransformation of the neurotoxic plasticiser n-butylbenzenesulfonamide (NBBS) were studied in order that the human health risk due to environmental exposure to NBBS could be evaluated. The pharmacokinetics of NBBS was determined in Wistar rats, following intravenous administration of the isotopomer [13C6] NBBS (1 mg/kg in 0.9% saline). [13C6] NBBS is cleared from plasma at a rate of 5 ml/min by the liver. The plasticiser has a short distribution phase (t1/2 of 47 seconds) and a long terminal phase (t1/2 of 17 hours). Plasma [13C6] NBBS concentrations, 24 hours after administration, represented 0.04% of the administered dose. These data indicated rapid uptake into tissue, which was subsequently confirmed by monitoring tissue concentrations of [13C6] NBBS for upto 8 hours following administration. [13C6] NBBS was not accumulated by any of the tissues studied (brain, liver, kidney, muscle and adipose tissue). Oral bioavailability was determined by simultaneously administering native NBBS orally and [13C6] NBBS intravenously to Wistar rats. The plasticiser was found to be absorbed erratically and subject to first pass metabolism. Plasma concentrations of orally administered NBBS fluctuated over the duration of the experiment. Furthermore, limitations posed by the assay resulted in truncated oral curves. These factors precluded estimation of areas under the oral NBBS curves to infinity and partial area ratios were instead used to calculate absolute bioavailability (mean of 19%). Cerebrovascular permeability of NBBS was determined with [13C6] NBBS, in Sprague-Dawley rats, using the in-situ brain perfusion technique of Takasato et al. (1984). The uptake of [13C6] NBBS into brain was very rapid and flow limited. Assuming an average cerebral perfusion fluid flow rate of 0.11 ml/s/g, the calculated single pass extraction value for [13C6] NBBS is 99.9% with a Kin of 0.11 ml/s/g. This is in close agreement with experimental values for the 15 second saline perfusions (extraction = 98% - 125% and Kin = 0.108 - 0.137). Differences in regional brain distribution of the plasticiser were not found. In-vitro biotransformation studies revealed one phase I metabolite in incubates of NBBS containing human, rabbit and rat post-mitochondrial supernatant (S9 fraction). This metabolite is 2-hydroxy-n-butylbenzenesulfonamide (NBBS-OH hydroxylated in the Based on these data, environmental exposure to NBBS does not pose a significant human health risk.
| Identifer | oai:union.ndltd.org:ADTP/187745 |
| Date | January 1997 |
| Creators | Samiayah, Ganesh Kumar, School of Physiology & Pharmacology, UNSW |
| Publisher | Awarded by:University of New South Wales. School of Physiology & Pharmacology |
| Source Sets | Australiasian Digital Theses Program |
| Language | English |
| Detected Language | English |
| Rights | Copyright Ganesh Kumar Samiayah, http://unsworks.unsw.edu.au/copyright |
Page generated in 0.0104 seconds